No Prescription |
 |
 | ||
|
Promensil Generic Red Clover Isoflavones |
|
| ||
No Prescription » Prescription Drugs 13 » Promensil Generic Red Clover Isoflavones A clinically proven natural product with 40mg of red clover isoflavones for the relief of hot flushes/flashes and night sweats with the additional benefits of maintaining bone and heart health.Promensil offers clinically supported natural products for women to maintain and enhance their vigour well being health and quality of life.Formulated with red clover isoflavones Promensil Menopause helps relieve menopause symptoms including hot flushes hot flashes and night sweats as well as supporting bone and heart health making it an ideal alternative to Hormone Replacement Therapy (HRT).Promensil Vitality is specially formulated with red clover isoflavones and calcium and Vitamin D to help treat and prevent osteoporosis and maintain heart health for women after menopause. Buy Promensil Generic Red Clover Isoflavones and other Prescription Drugs 13 products online at Medstore. 233
About Promensil Generic Red Clover Isoflavones: Product Type: Prescription Drugs 13 Promensil ( Generic Red Clover Isoflavones ) Promensil (Generic Red Clover Isoflavones) Generic Red Clover Isoflavones 40mg 30 tabs Generic Red Clover Isoflavones Promensil
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
